Skip to main content
SpringerLink
Log in

Antirheumatika und Antiphlogistika

  • Chapter
Book cover Arzneiverordnungs-Report 2016

Zusammenfassung

Bei den Verordnungen der Antirheumatika und Antiphlogistika dominieren auch 2015 mit klarem Abstand die nichtsteroidalen Antiphlogistika. Unter diesen steht Ibuprofen weiterhin, inzwischen mit großem Vorsprung, an erster Stelle vor Diclofenac in der Verordnungshäufigkeit. Die Verordnungen der zwei auf dem Markt verbliebenen selektiven Cyclooxygenase-2-Hemmer haben leicht zugenommen, sie machen jedoch nur 10% der Gesamtverordnungen bei den nichtsteroidalen Antiphlogistika aus.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Alcorn N, Saunders S, Madhok R (2009): Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 32: 1123–1134

    Article  CAS  PubMed  Google Scholar 

  • Bhosale UA, Quiraishi N, Yegnanarayan R, Devasthale D (2015): A comparative study to evaluate the cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients. J Basic Clin Physiol Pharmacol 26: 73–79

    CAS  PubMed  Google Scholar 

  • Cannon CP, Curtis SP, Fitzgerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, Van Der Heijde D, Erdmann E, Laine L (2006): Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368: 1771–1781

    Article  CAS  PubMed  Google Scholar 

  • Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ (2002): Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104–2110

    Article  CAS  PubMed  Google Scholar 

  • Charatan F (2002): Arthritis drug should be removed from market, says consumer group. Brit Med J 324: 869

    Article  PubMed  PubMed Central  Google Scholar 

  • Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ (2016): Leflunomide use and risk of lung disease in rheumatoid arthritis: A systematic literature review and metaanalysis of randomized controlled trials. J Rheumatol 43: 855–860

    Article  PubMed  Google Scholar 

  • Coxib and traditional NSAID Trialists’ (CNT) Collaboration (2013): Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382: 769–779

    Article  Google Scholar 

  • Cryer B, Feldman M (1998): Cyclooxygenase-1 and cyclooxygenase- 2 selectivity of widely used nonsteroidal antiinflammatory drugs. Am J Med 104: 413–421

    Article  CAS  PubMed  Google Scholar 

  • Day R (2002): Another selective COX-2 inhibitor: more questions than answers? J Rheumatol 29: 1581–1582

    PubMed  Google Scholar 

  • European Medicines Agency (2005): Public Statement. European Medicines Agency announces regulatory action on COX-2 inhibitors. Publiziert am 17. Februar 2005 unter: http://www.emea.eu.int/htms/hotpress/d6275705.htm

  • European Medicines Agency (2007): Press release. European Medicines Agency recommends restricted use for piroxicam. Publiziert am 25. Juni 2007 unter: http://www.emea.europa.eu/pdfs/human/press/pr/26514407en.pdf

  • European Medicines Agency (2012): European Medicines Agency finalises review of recent published data on cardiovascular safety of NSAIDs. Press release 19.10.2012 FDA-Statement (2004): FDA-Statement on Naproxen. Publiziert am 20. Dezember 2004 unter: http://www.fda.gov/bbs/topics/news/2004/new01148.html

  • Fu JY, Masferrer JL, Seibert K, Raz A, Needlemam P (1990): The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265: 16737–16740

    CAS  PubMed  Google Scholar 

  • Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, Tindall E, Triadafilopoulos G, Stromatt SC, Teoh LS (1993): Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 119: 257–262

    Article  CAS  PubMed  Google Scholar 

  • Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD Logan RF, Murphy M, Vessey MP, Colin-Jones DG (1994): Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 323: 1075–1052

    Article  Google Scholar 

  • Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR (1993): Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90: 11693–11697

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Patrono C, Baigent C (2015): Nonsteroidal anti-inflammatory drugs and the heart. Circulation 129: 907–916

    Article  Google Scholar 

  • Piroxicam Rote-Hand-Brief (2007): Neue Anwendungsbeschränkungen für die systemische Anwendung von Piroxicam aufgrund gastrointestinaler Nebenwirkungen und Hautreaktionen. Internet: http://www.akdae.de/20/40/Archiv/2007/40-20071011.pdf

  • Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Haim M, Reginster JY (2004): Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a metaanalytic approach. Ann Rheum Dis 63: 759–766

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O’Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016): 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68: 1–26

    Google Scholar 

  • Smolen JS, Aletaha D, McInnes IB (2016): Rheumatoid arthritis. Lancet 2016 May 3. pii: S0140-6736(16)30173–8. doi:10.1016/S0140-6736(16)30173-8. [Epub ahead of print]

    Google Scholar 

  • Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2014): EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73: 492–509

    Article  CAS  PubMed  Google Scholar 

  • Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators (2005): Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071–1080

    Article  CAS  PubMed  Google Scholar 

  • Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P (2011): Cardiovascular safety of non-steroidal anti-inflammatory drugs: network metaanalysis. Brit Med J 342: c 7086 1–11

    Google Scholar 

  • Vane JR (1971): Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232–235

    Google Scholar 

  • Wolfe MM, Lichtenstein DR, Singh G (1999): Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888–1899

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, 20246, Hamburg

    Prof. Dr. med. Rainer H. Böger

  2. Institut für Pharmakologie und Toxikologie der Universität, Robert-Koch-Straße 40, 37075, Göttingen

    Prof. Dr. med. Gerhard Schmidt

Authors
  1. Prof. Dr. med. Rainer H. Böger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Gerhard Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Böger, R., Schmidt, G. (2016). Antirheumatika und Antiphlogistika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2016. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50351-5_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-50351-5_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-50350-8

  • Online ISBN: 978-3-662-50351-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation